Drugs / Peg-IFN
Peg-IFN
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT07069569 | Jun 2025 → Jul 2027 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT04676724 | Jan 2021 → Feb 2023 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT04225715 | Jul 2020 → Jul 2024 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT01625338 | Jun 2012 → Oct 2014 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT01938781 | Jun 2013 → Dec 2016 | fibrotic liver disease | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01743521 | Jan 2013 → Nov 2015 | chronic hepatitis C virus infection | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00979706 | Mar 2005 → Nov 2014 | HIV infectious disease | Juan A. Arnaiz | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 1 | NCT01582035 Background | Apr 2012 → Nov 2013 | hepatitis C virus infection | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00983060 Background | Sep 2009 → Apr 2011 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00774397 Comparator | Oct 2008 → Nov 2011 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT01608737 Comparator | Sep 2012 → Oct 2015 | chronic hepatitis C virus infection | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 3 | NCT01405560 Background | Sep 2011 → Mar 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01405937 Background | Aug 2011 → Feb 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01330316 Background | Jul 2011 → Jun 2014 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01370642 Background | Jun 2011 → Jul 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| — | NCT02113631 Comparator | Sep 2011 → Apr 2013 | chronic hepatitis C virus infection, cirrhosis of liver | Louis Stokes VA Medical Center | Completed | No outcome recorded |
Press releases naming this drug 11 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peg IFN | “BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)” NCT00983060 ↗16“pegylated interferon alfa (Peg IFN)(180ug subcutaneous once weekly)” NCT01582035 ↗ “PegIFN is to be injected once per week for 24 or 48 weeks.” NCT01582035 ↗ |
| Known as | pegylated interferon | “Pegylated Interferon (PegIFN) and ribavirin (RBV)” NCT01330316 ↗1“pegylated interferon (Peg-IFN)” NCT01625338 ↗ |
| Known as | pegylated interferon alfa | “pegylated interferon alfa (Peg IFN)(180ug subcutaneous once weekly)” NCT01582035 ↗ |
| Known as | pegylated-interferon a2b | “weekly sc pegylated-interferon a2b (Peg-INF)(1.5 mcg/kg/week)” NCT00979706 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Peg-IFN” NCT01370642 ↗ |
| Route | Subcutaneous | “weekly sc pegylated-interferon a2b” NCT00979706 ↗ |